PMID: 11315341Apr 24, 2001Paper

Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus

Lupus
M Østensen, P M Villiger

Abstract

Up to 80% of patients with systemic lupus erythematosus (SLE) are treated with nonsteroidal anti-inflammatory drugs (NSAID) for musculoskeletal symptoms, serositis and headache. This survey reviews the literature on non-selective and selective inhibitors of cyclooxygenases with an emphasis on the efficacy and safety profile reported in SLE patients. No lupus-specific data on gastro-intestinal side effects of NSAID exist. Both non-selective Cox-inhibitors and selective Cox-2 inhibitors induce renal side effects including sodium retention and reduction of the glomerular filtration rate. Lupus nephritis is a risk factor for NSAID-induced acute renal failure, but not for rare idiosyncratic toxic renal reactions to NSAID. In refractory nephrotic syndrome, NSAID have been used successfully. Cutaneous and allergic reactions to NSAID are increased in SLE patients as well as hepatotoxic effects, particularly with high dose aspirin. Whereas a variety of central nervous system side effects of NSAID are probably no more common in SLE patients than in others, aseptic meningitis has been reported more frequently. Ovulation and pregnancy can be adversely affected by Cox-inhibitors. The antiplatelet effect of aspirin and non-selective Cox-inhi...Continue Reading

References

Dec 2, 1978·British Medical Journal·R L Travers, G R Hughes
Mar 1, 1976·Arthritis and Rheumatism·W E Seaman, P H Plotz
Jan 1, 1990·American Journal of Nephrology·J E HeegD de Zeeuw
Feb 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G V WarrenE J Lewis
Aug 1, 1988·Baillière's Clinical Rheumatology·A L Tonkin, L M Wing
May 1, 1985·Journal of the American Academy of Dermatology·M Bigby, R Stern
Jul 1, 1982·Archives of Internal Medicine·G D ParkM Goldberg
Mar 1, 1984·The New England Journal of Medicine·D M Clive, J S Stoff
Apr 13, 1995·The New England Journal of Medicine·M A KhamashtaG R Hughes
Jan 1, 1996·British Journal of Rheumatology·M AkilP Stewart
Mar 15, 1997·Annals of the New York Academy of Sciences·C D Breder
Aug 3, 1999·Clinical Pharmacology and Therapeutics·J RossatM Burnier
Oct 27, 1999·Rheumatology·S M SultanD A Isenberg
Jan 22, 2000·Arthritis and Rheumatism·L J CroffordL B van de Putte

❮ Previous
Next ❯

Citations

Jul 20, 2002·Current Rheumatology Reports·David Hermosillo-Romo, Robin L Brey
Jan 16, 2008·The Neurologist·Jamal MikdashiAllan Krumholz
Nov 4, 2009·Mediators of Inflammation·Manfred Kunz, Saleh M Ibrahim
Jul 1, 2010·Therapeutic Advances in Chronic Disease·Maame B Amissah-Arthur, Caroline Gordon
Apr 19, 2002·Paediatric Drugs·Luis CarreñoIndalecio Monteagudo
Mar 23, 2010·International Journal of Clinical Rheumatology·Carly Skamra, Rosalind Ramsey-Goldman
May 14, 2009·Current Medical Research and Opinion·Kenneth Kalunian, Joan T Merrill
Aug 6, 2015·Medicina clínica·Belén Andrés-del OlmoFrancisco Javier Sanz Sanz
Nov 10, 2012·Rheumatic Diseases Clinics of North America·Joseph Mosak, Richard Furie
Jul 14, 2009·Best Practice & Research. Clinical Rheumatology·Jennifer M Grossman
May 20, 2008·Seminars in Cutaneous Medicine and Surgery·Manfred Kunz
Jun 4, 2002·Best Practice & Research. Clinical Rheumatology·John M Esdaile
Oct 25, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Davood RostamzadehMehdi Yousefi
Apr 20, 2017·Journal of Immunoassay & Immunochemistry·Haseeb Ahsan
Feb 3, 2011·The Journal of Rheumatology·Alexandra M Tiliakos, Doyt L Conn
Sep 25, 2018·BMJ Global Health·Elopy N SibandaFrancisca Mutapi
Feb 28, 2018·Current Drug Discovery Technologies·Hamid FarhangAbbas Mirshafiey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.